CSF2 and COVID-19: Several clinical trials have investigated the use of monoclonal antibodies to treat COVID-19 by modulating the immune response via GM-CSF or its receptor (GM-CSFR) to reduce the inflammatory signaling activated by the GM-CSF axis.